FONT-SIZE Plus   Neg

Arca Continental Q1 Profit Rises

Coca-Cola bottler Arca Continental, S. A. B. de C. V. (EMBVF.PK) Friday posted higher net profit for the first quarter reflecting increased revenue for the period, primarily led by a sales rise in North America.

For the quarter, the company reported net income of 1.09 billion peso, up 11.3 percent from 979 million peso last year.

Revenue for the quarter was 13.375 billion peso, up 8.3 percent from 12.35 billion peso a year back. Net sales in North America for the quarter was 9.989 billion peso, up from 9.144 billion peso last year.

Commenting on the results, Francisco Egloff, CEO of Arca Continental said, "During the first quarter of 2013 we continued to focus on satisfying our clients and consumers while increasing the efficiency of our operations, which translated into improved profitability with EBITDA up 16.8 percent versus last year. The actions that had the most impact were the optimization of our pricing structure, cost improvements and perfecting our execution at the point of sale; combined, these steps enabled us increase our market share and strengthen our leading position in the various categories and territories in which we participate."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Visa Inc. (V) on Monday reported an increase in profit for the fourth quarter, as revenues jumped driven largely by increase in customer spending and inclusion of Europe business. Earnings and revenues trumped Wall Street expectations. Foster City, California-based Visa's fourth-quarter profit rose... As Sony Corp. prepares to launch the new PlayStation 4 Pro gaming console on November 10, several new games that are compatible with the console have also been confirmed for launch. Game developers are readying to provide PlayStation 4 Pro support for many games on PS4. Shares of Advaxis Inc. dropped more than 13 percent in pre-market activity before paring losses to just more than 5 percent after the company said that it was not able to complete the second stage of the Phase 2 GOG-0265 trial as designed due to a clinical hold that affected its clinical development programs last year.
comments powered by Disqus
Follow RTT